Inflammatory Bowel Disease (IBD)


Inflammatory Bowel Disease (IBD) is comprised of Crohn’s disease and ulcerative colitis - two serious, chronic diseases directly affecting the digestive system causing intestinal tissue to become inflamed, form sores, and bleed easily. The incidence of IBD is rising in developing countries around the world and approximately 5 million people worldwide are currently affected by a form of IBD.

This chronic condition is without a medical cure and commonly requires a lifetime of care. With the advent of monoclonal antibodies for use in IBD there has been a breakthrough in disease management while many more biologics are in the pipeline. Currently the global market is estimated at $16 billion and this is set to continue to rise.

Biomedcode offers services of preclinical drug efficacy evaluation of therapeutics using spontaneous and induced mouse models of inflammatory bowel disease (IBD) and TNBS colitis.